Posted by Michael Wonder on 08 Oct 2024
Indivior's Sublocade rapid induction/alternative injection site prior approval supplement receives FDA priority review
7 October 2024 - Indivior today announced the prior approval supplement for Sublocade (buprenorphine extended release) injection submitted by Indivior has been granted priority review designation by the US FDA.
The PDUFA action date for this submission is set for 7 February 2025.
